GRB2 and prostate carcinoma: We investigated the effect of GRB2 expression on time to recurrence that was defined according to the European Association of Urology criteria (https://uroweb.org/guideline/prostate-cancer/): PSA > 0.2 ng/mL and rising after RP; PSA > nadir + 2 ng/mL after RT; and PSA rising, with serum testosterone < 50 ng/mL, after hormonal therapy.